Wednesday, 28 Jun 2017

You are here

One-Third of FDA Approvals Need Post-Marketing Safety Changes

One-third of newly approved drugs in the next decade will require new safety warnings based on pharmacovigilance, according to a new study in JAMA. (Citation Source: http://buff.ly/2r3dYUs)

An analysis by the Food and Drug Administration (FDA), looked at all 222 prescription drugs (183 pharmaceuticals and 39 biologics) approved between 2001 through 2010.

They identified 71 new drugs with 123 new postmarket safety events (3 withdrawals, 61 boxed warnings, and 59 safety communications) during a follow-up period of 11.7 years. The overall proportion drugs affected by a postmarket safety event at 10 years was 32%.  The median time from approval to first postmarket safety event was 4.2 years.

These events resulted in either black-box warnings and lesser alerts (warnings, cautions) for many of these drugs, with only 3 being withdrawn from th market (Bextra, Raptiva, Zelnorm).

These findings were significantly more frequent among biologics (incidence rate ratio [IRR] = 1.93), psychiatric agents, those drugs receiving accelerated approval and those with near–regulatory deadline approval. 

Post-marketing safety events were found in 32% of new drugs approved by the FDA from 2001 through 2010. Biologics, psychiatric therapeutics, and accelerated and near–regulatory deadline approval agents were at greater risk for new, evolvig safety events, suggesting an ongoing need for pharmacovigilance with new agents.

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Suspending Methotrexate for Influenza Vaccination

Vaccinating our rheumatoid arthritis patients against influenza every year is a safety priorty. However immunosuppressive therapies pose a challenge to vaccine administration as their use can hamper vaccine immunogenicity.

Debate over Alcohol and Methotrexate Precautions

Drs. Kremer and Weinblatt have responded to a recent Annals of Rheumatic Disease article regarding the hepatic risks of alcohol use with methotrexate (MTX) therapy authored by Humphries et al. (Citation source: http://buff.ly/2r70uuz)

NSAIDs Increase Risk of Acute Myocardial Infarction

Using data from Canadian and European healthcare databases, the BMJ has reported that all NSAIDs, including celecoxib and naproxen, increase the risk of acute myocardial infarction.

While the recent 24,081 patient PRECISION study showed noninferiority between celecoxib, naproxen and ibuprofen with regard to CV risk, that study did not include a placebo arm.

Paradoxical Toxicities with TNF Inhibitors

Something is curiously wrong when a drug induces the disease it is intended to treat. Yet this phenomenon has been described with all five FDA-approved TNF inhibitors.

Acute Steroid Use Comes with Risk

Steroids are known for their acute therpeutic wonders and chronic hazards. Hence most practitioners are comfortable using short term, limited dose corticosteroids for a variety of ailments.